# Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

> **NCT07168902** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bausch & Lomb Incorporated** · enrollment: 252 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** BL1107 Low dose
- **DRUG:** BL1107 High dose
- **DRUG:** Timolol maleate 0.5%

## Key facts

- **NCT ID:** NCT07168902
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-24
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07168902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07168902, "Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07168902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*